CD274 and nasal cavity and paranasal sinus carcinoma: FDA-approved biomarker dMMR or MSI-H for PD-1/PD-L1 ICI treatment decision for tumors regardless of their primary site of origin [35], however, has not yet been comprehensively investigated in sinonasal carcinomas.